Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Sopheon Funding Award

19 Oct 2017 07:00

RNS Number : 9906T
Sopheon PLC
19 October 2017
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon Awarded Funding for European Research Projects

 

Funding recognizes Sopheon's ongoing contribution to research on market disrupters such as Internet of Things, real-time decision support, and advanced analytics embedded into business process

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today announced the award of European funding for innovative research in the framework of the EUREKA/ITEA research program alongside a consortium of project partners. The funding is for two different projects, Medolution (https://itea3.org/project/medolution.html) and PARTNER (https://itea3.org/project/partner.html).

 

Both research projects focus on developing innovative and intelligent methods and software for real time handling of massive volumes of data across complex scenarios, with emphasis on the healthcare industry. Sopheon's contribution to these projects focuses on applying the data-driven decision support capabilities of our Accolade® software. Sopheon benefits in return from the collaboration with project partners − research institutes and leading software companies such as Philips Healthcare, Atos/Bull, Siemens Healthcare, Barco, IMEC, KPN and NXP Semiconductors - to develop breakthrough capabilities for commercial application in our software.

 

In the current digital age, organizations are looking for technologies that allow them to handle unprecedented amounts of information, with speed. This information is drawn from a very incoherent landscape of IT systems and sources, within as well as beyond the physical boundaries of the enterprise. The data to be handled comes from many different sources - structured and unstructured data; metadata from sensor data, images, video - and is reused in the context of big data analysis, internet of things (IoT) techniques, cloud services, etc.

 

The Accolade software is able to interpret all of this data in real time, irrespective of source or format, based on rules and criteria defined by domain experts and within predefined best practice protocols that are managed by the Accolade system.

 

Huub Rutten, VP Research and Application Development at Sopheon, stated: "For Sopheon the research is very applicable to our core enterprise innovation management clients and future product strategy. Our work in these projects positions us to develop relationships with some of the leading companies in the world for commercial leverage, and to develop innovative strategic technologies and applications for our target markets. Further, our research discoveries also have the potential to open new market segments for our application."

 

This award brings to a total of five the number of research grants awarded to Sopheon since 2009.

 

Sopheon® and Accolade® are trademarks of Sopheon 

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

 

About Eureka. EUREKA (http://www.eurekanetwork.org/) is an intergovernmental organization for pan-European research and development funding and coordination. EUREKA aims to coordinate efforts of governments, research institutes and commercial companies concerning innovation.

 

About ITEA. ITEA (https://itea3.org/) is the EUREKA Cluster program supporting innovative, industry-driven, pre-competitive R&D projects in the area of Software-intensive Systems & Services (SiSS). ITEA stimulates projects in an open community of large industry, SMEs, universities, research institutes, and user organizations.

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKFDNQBDDQKD
Date   Source Headline
3rd Nov 202310:15 amRNSForm 8.5 (EPT/NON-RI)
3rd Nov 20238:54 amRNSForm 8.3 - Rivomore Limited - Sopheon plc
2nd Nov 20239:34 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 20233:44 pmEQSForm 8.3 - Apex Fundrock Limited : Form 8.3 Apex Fundrock Limited Re: Sopheon PLC
1st Nov 20231:55 pmRNSForm 8.3 - Sopheon plc
1st Nov 202311:23 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 202310:51 amGNWForm 8.3 - [Sopheon plc - Opening Declaration - 31 03 2023] - (CGAML)
1st Nov 202310:35 amRNSForm 8.3 - Sopheon PLC
31st Oct 20231:00 pmRNSStatement re Possible Offer
24th Aug 20237:00 amRNSInterim Results
10th Jul 20237:00 amRNSAcquisition
15th Jun 20235:06 pmRNSIssue of Equity
8th Jun 20231:35 pmRNSResult of AGM
8th Jun 20237:00 amRNSAGM Statement
13th Apr 20234:20 pmRNSIssue of Equity
31st Mar 20239:14 amRNSIssue of Equity
27th Mar 20234:23 pmRNSDirector Shareholdings
24th Mar 20237:00 amRNSDirector Share Purchases
23rd Mar 20237:00 amRNSFinal Results
22nd Feb 20234:59 pmRNSIssue of Equity
6th Feb 20237:00 amRNSDirectorate Change and Notice of Results
30th Jan 20237:00 amRNSTrading Update
20th Sep 202212:01 pmRNSSopheon launches Acclaim Line of SaaS Offerings
2nd Sep 202210:06 amRNSIssue of Equity
1st Sep 20227:00 amRNSNew Release of Award-winning Innovation Product
24th Aug 20227:00 amRNSInterim Results
16th Aug 20227:00 amRNSFive-year, $11.2m Enterprise Agreement
3rd Aug 202210:18 amRNSHolding(s) in Company
21st Jun 202212:20 pmRNSHolding(s) in Company
9th Jun 20222:30 pmRNSResult of AGM
9th Jun 20227:00 amRNSAGM Statement
6th Jun 20226:02 pmRNSIssue of Equity & TVR
23rd May 20227:00 amRNSDirector Dealing & Issue of Equity
18th May 20227:00 amRNSAcquisition
29th Apr 20225:12 pmRNSHolding(s) in Company
7th Apr 20227:00 amRNSNew Sopheon Software Release
1st Apr 202212:10 pmRNSDirector Shareholdings
24th Mar 20227:00 amRNSFinal Results
25th Jan 20227:00 amRNSTrading Update
17th Jan 20223:15 pmRNSIssue of Equity
20th Dec 20217:00 amRNSAcquisition and Trading Update
24th Sep 20211:52 pmRNSIssue of Equity
16th Sep 202110:00 amRNSHolding(s) in Company
13th Sep 20215:24 pmRNSIssue of Equity
31st Aug 20216:14 pmRNSDirector Shareholdings
25th Aug 20217:00 amRNSInterim Results
13th Jul 20217:00 amRNSNew Release Drives Business Transformation
23rd Jun 20217:00 amRNSSopheon Earns Authority to Operate for NAVSEA
15th Jun 20219:54 amRNSIssue of Equity
10th Jun 202111:43 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.